Vipul Jairath
A5008693009- Inflammatory Bowel Disease
- Microscopic Colitis
- Eosinophilic Esophagitis
- Celiac Disease Research and Management
- Health Systems, Economic Evaluations, Quality of Life
- Autoimmune and Inflammatory Disorders
- Colorectal Cancer Screening and Detection
- Gastrointestinal Bleeding Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Biosimilars and Bioanalytical Methods
- Helicobacter pylori-related gastroenterology studies
- Liver Diseases and Immunity
- Diverticular Disease and Complications
- Immunodeficiency and Autoimmune Disorders
- Pharmaceutical studies and practices
- Anorectal Disease Treatments and Outcomes
- Colorectal Cancer Treatments and Studies
- Gastrointestinal motility and disorders
- Chronic Lymphocytic Leukemia Research
- Gastrointestinal disorders and treatments
- Diagnosis and treatment of tuberculosis
- Gastrointestinal Tumor Research and Treatment
- Pregnancy and Medication Impact
- Esophageal and GI Pathology
- Health and Medical Research Impacts
Western University
2016-2025
Lawson Health Research Institute
2022-2025
University Gastroenterology
2019-2025
London Health Sciences Centre
2018-2024
John Radcliffe Hospital
2011-2024
University College London
2007-2024
Cleveland Clinic
2024
Mayo Clinic in Arizona
2024
St Joseph's Health Care
2024
University Hospital
2019-2022
BackgroundManagement strategies and clinical outcomes vary substantially in patients newly diagnosed with Crohn's disease. We evaluated the use of a putative prognostic biomarker to guide therapy by assessing randomised either top-down (ie, early combined immunosuppression infliximab immunomodulator) or accelerated step-up (conventional) treatment strategies.MethodsPROFILE (PRedicting Outcomes For disease using moLecular biomarker) was multicentre, open-label, biomarker-stratified,...
Approximately half the patients with ulcerative colitis who undergo restorative proctocolectomy ileal pouch-anal anastomosis (IPAA) will subsequently have pouchitis, and among those patients, one fifth chronic pouchitis. We conducted a phase 4, double-blind, randomized trial to evaluate vedolizumab in adult whom pouchitis had developed after undergoing IPAA for colitis. Patients were assigned (in 1:1 ratio) receive intravenously at dose of 300 mg or placebo on day 1 weeks 2, 6, 14, 22, 30....
Background Patient-reported outcomes (PROs) have an increasingly important role in the evaluation of new therapies for inflammatory bowel disease. The US Food and Drug Administration has issued formal guidance to describe PRO instruments claims product labelling. However, no validated exists ulcerative colitis. Aim To investigate whether PROs from Mayo Clinic Score (MCS) UC can be modified, develop interim use clinical trials, alone or combination with endoscopy. Methods Data induction trial...
As more treatment options for inflammatory bowel diseases become available, it is important to identify patients most likely respond different therapies. We created and validated a scoring system with Crohn's disease (CD) who vedolizumab.
BACKGROUND & AIMS Although biologics have revolutionized treatment of Crohn's disease (CD), an efficacy ceiling has been reached. Combining biologic therapies may improve remission rates. METHODS EXPLORER, a phase 4, single-arm, open-label study, evaluated triple combination therapy with vedolizumab (300 mg on day 1, weeks 2 and 6, then every 8 weeks), adalimumab (160 2, 80 at week 40 methotrexate (15 weekly) in biologic-naïve patients newly diagnosed, moderate- to high-risk CD. Endoscopic...
Eosinophilic esophagitis (EoE) is a chronic immune-mediated rare disease, characterized by esophageal dysfunctions. It likely to be primarily activated food antigens and classified as disease for most patients. Therefore, deeper understanding of the pathogenetic mechanisms underlying EoE needed implement improve therapeutic lines intervention ameliorate overall patient wellness.